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Three single-chain antibody fragments that recognize the
extracellular human interferon y receptor a-chain (IFNyR),
and inhibit the binding of human IFNy, have been produced
in Escherichia coli. These fragments are derived from
murine anti-receptor monoclonal antibodies, and comprise
the variable heavy (VH) domain linked to the variable light
(VJ chain through a 15 amino acid linker [(GGGGS)3].
Using surface plasmon resonance technology (BLAcore),
the soluble proteins were shown to retain a high affinity
for recombinant IFNyR, and by radiohnmunoassay to
possess high inhibitory activity towards IFNy-binding to
human Raji cells. The antibody fragments most likely
recognize epitopes that overlap the cytokine binding site
on the receptor surface. Attempts to dissect further the
antibodies to isolated VH- and VL-chains and to synthetic
linear and cyclic peptides derived from the individual
complementarity determining regions failed to afford frag-
ments with significant IFNyR binding affinity. Nevertheless,
these native-like variable region fragments and petidomi-
metics derived from them are of interest in the design of
novel IFNyR antagonists.
Keywords: antagonist/epitope/Fv fragment/ligand design/
mimetic/monoclonal antibody
Introduction
The physico-chemical basis of the binding of protein ligands
at specific sites on the surface of receptor proteins is not well
understood. The extracellular portion of the human interferon
y receptor a-chain (IFNyR) is an interesting target for studies
of protein—protein recognition, since both the natural ligand
and several surrogate ligands in the form of neutralizing
anti-receptor monoclonal antibodies (mAbs) are available for
investigation (Aguet and Merlin, 1987; Garotta et al, 1990).
Moreover, the crystal structure of the IFNy-IFNyR was solved
recently, which revealed in atomic detail the residues on the
receptor that are buried upon complex formation with the
cytokine (Walter et al, 1995). It is then of interest to enquire
how the structural epitopes bound by neutralizing anti-IFNyR
mAbs are related to the ligand binding site on the receptor
surface. The study of such neutralizing mAbs is also fuelled
by the prospect that fragments derived from them may provide
a useful starting point in the design of novel small molecule
EFNyR antagonists.
In some cases much smaller fragments of an antibody may
retain the ability to interact selectively with a protein antigen.
This includes the Fv fragment (Raag and Whitlow, 1995),
which contains an intact copy of the antigen binding site, as
© Oxford University Press
well as the individual H-chain or L-chain variable regions
(Ward et al, 1989; Hamers-Casterman et al., 1993; Davies
and Riechmann, 1995; Monfardini et al., 1995), each with just
three complementarity determining regions (CDRs). Even
relatively small linear and cyclic peptides derived from the
sequences of individual CDRs of some mAbs have been
identified that retain a weak antigen-binding activity (Saragovi
et al, 1992; Doring et al, 1994).
The diverse functions of IFNy in host defence, inflammation
and autoimmunity arise through its association with the IFNyR
(Farrar and Schreiber, 1993). This -90 kDa transmembrane
glycoprotein binds IFNy with high affinity (KD = 10~10 M),
and consists of an extracellular portion of 229 amino acid
residues folded into two Ig-like domains, a single transmem-
brane region of 22 residues and an intracellular region of 221
residues. The recombinant extracellular portion alone, as well
as the intact membrane-bound receptor, binds IFNy tightly in
a 2:1 receptonligand stochiometry (Fountoulakis et al., 1992;
Greenlund et al, 1993), as revealed recently in the X-ray
crystal structure of the IFNy-IFNyR complex (Walter et al,
1995). IFNy-induced signal transduction, however, requires a
species-specific interaction of the a-chain-hormone complex
with a separate transmembrane receptor p" subunit (Hemmi
et al, 1994; Soh et al, 1994; Marsters et al, 1995), and
additional receptor subunits may be required to mediate the
anti-viral actions of IFNy (Soh et al, 1994). IFNyR antagonists
are of potential value in the treatment of autoimmune diseases,
chronic inflammations, allograft rejection and delayed-type
hypersensitivity.
An understanding of IFNyR recognition by mAbs will
require high-resolution structural data on mAb fragment-
receptor complexes, as well as the ability to produce mutants
for structure-function studies. For both goals, an important
step is the production in Escherichia coli of soluble scFv
fragments. The variable region cDNAs encoding the H- and
L-chains of the neutralizing anti-IFNyR mAbs A6, yR38 and
yR99, studied here, have been described in previous work
(Bridges et al, 1995). The first two mAbs bind overlapping
epitopes contained entirely widiin the N-terminal Ig-like
domain of the IFNyR, between residues 1 and 108, whereas
the last mAb binds an epitope within the membrane proximal
Ig-like domain, between residues 105 and 229 (Ruegg et al,
1995; Williams et al, 1995). In all three cases, the mAbs
recognize conformational (i.e. discontinuous) epitopes.
Materials and methods
Polymerase chain reaction
Amplifications were carried out in a reaction volume of 100 (il
under mineral oil containing the following: dNTPs (0.2 mM
of each), MgCl2 (1-5 mM), sense and antisense primers (1 \xM),
plasmid or cDNA, and the recommended buffer (AmpliTaq or
Vent). Filter tips were used throughout. The reactions were
performed using a Perkin-Elmer 480 thermal cycler as follows:
5 min at 95°C, 1 min at 94°C, 2 min at 55°C and 2 min at 72°C.
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DNA sequencing and analysis
The sequences of all the scFv and individual VH and VL genes
cloned in pHENl were verified by dideoxy sequencing (Sanger
et al, 1977) of plasmid DNA isolated from E.coli TGI using
Sequenase (USB) and the following primers:
HENLEFT 5'-GCTATGACCATGATTACGCCAGCTT-3'
HENRIGHT 5'-CGATCTAAAGTTTTGTCGTCTTTCC-3'
LINKFORNEW 5'-TGGAGACTGAGTGAGCTCGATGTC-3'
LINK- 5'-GGCACCACGGTCACCGTGTGGTGA-3'
BACKNEW
Variable region gene assembly
To assemble scFv genes, VH and VL cDNAs (Bridges et al.,
1995) were amplified by PCR using the Heavy and Light
Primer Mixes in the Mouse scFv Module of the Pharmacia
(Pharmacia Biotech, Uppsala, Sweden) Recombinant Phage
Antibody System. The scFv gene was then assembled by PCR
using the Linker-Primer Mix and RS-Primer Mix, according
to the manufacturer's instructions (Pharmacia). The resulting
product was rendered blunt-ended with T4 DNA polymerase
and concatenated by ligation to improve subsequent digestion
with Notl and Sfil, before ligation into the vector pHENl
(Hoogenboom et al, 1991).
The individual VH and VL cDNAs were amplified by PCR,
using the appropriate M13 clone (Bridges et al, 1995) as
template, and the following primers (Hoogenboom etal, 1991)
(Notl and Sfil restriction sites underlined):
VH1BACKSFI15 5 '-CATGCCATGACTCGCGGCCCAGCCGGCCATGG-
CCS AGGTSMARCTGC AGSAGTCWGG-3'
VH1FOR2NOT1 5'-TTCTGCGGCCGCTGAGGAGACGGTGACCGTG-
GTCCCTTGGCCCC-3'
VLPHENSFI 5'-ACGCGGCCCAGCCGGCCATGGCTGACGTCGT-
GATGACMCARWCKCCA-3'
VLPHENNOTI 5 '-TTCTGCGGCCGCCCGTTTCAGCTCCAGCTTGG-
TCCC-3'
The PCR products were then digested with Notl and Sfil
and cloned in pHENl, as above for the scFv genes.
Site-directed mutagenesis
Camelization of H-chains was carried out by site directed
mutagenesis using the Altered Sites II in vitro Mutagenesis
System (Promega, Madison, WI). VH genes were amplified by
PCR using the appropriate cDNA as template, the products
were digested with Xbal and AspllS and the products ligated
into the vector pALTER-1. The following oligonucleotides
were used for mutagenesis of A6, TR38 and yR99 H-chains,
respectively:
A6VHCAMEL1 5'-CGTCAGTCTTCAGGGAAGGAACGCGAGGGGC-
TGGCACACATTTGGTGGG -3 '
R38VHCAMEL1 5'-CCGCCAGTCTCCAGAGAAGGAGCGCGAGGGG-
GTTGCTGAAATTAGATTGA-3'
R99VHCAMEL1 5'-AAAACAGAGGCCTGGACAGGAACGCGAAGG-
GATTGGATACATTAATCCTA-3'
Clones carrying the desired mutation were identified by
DNA sequencing, and used as template for PCR using the
primers VH1BACKSFI15 and VH1FOR2NOT1. The products
were subsequently cloned into pHENl (see above).
Production and purification of scFvs
Escherichia coli HB2151 was transformed with phagemids
pOCI455 (pHENl + A6 scFv), pOCI456 (pHENl + yR38
scFv) and pOCI461 (pHENl + yR99 scFv), and transformants
were selected on 2XTY agar containing 1% glucose+100
Hg/ml ampicillin at 30°C. Colonies were then grown in 2XTY
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medium, also with 1% glucose+100 Jig/ml ampicillin at 30°C.
Cells were pelleted after growth to OD550 = 0.5-0.8, washed
once with 2TY medium and resuspended in TY medium with
100 |ig/ml ampicillin and 0.01 mM IPTG. After growth for a
further 16 h at 30°C, scFv was purified either from the culture
supernatant (for A6 and yR99) or from cells (for "yR38). For
the former, PMSF (1 mM) benzamidine (1 mM) and EDTA
(1 mM) were added to the culture, cells and debris were
removed by centrifugation and the supernatant was applied to
an imrr.unoaffinity column prepared by cross-linking anti-c-
myc tag mAb 9E10 (Evan et al, 1985) to protein-G Sepharose
(Pharmacia). The column was washed with Tris-HCl (50 mM,
pH 7.5), EDTA (1 mM) and NaN3 (0.04%), and bound protein
was eluted with glycine-HCl (50 mM, pH 2.5), EDTA (1 mM)
and NaN3 (0.04%). This was neutralized immediately with
sodium phosphate (4 M, pH 7). The protein was then applied
to a second immunoaffinity column, prepared by immobilizing
a thioredoxin-IFNYR1"108 (for A6 scFv), or a thioredoxin-
IFN7R100"229 (for T « 9 9 scFv) fusion protein (Ruegg et al,
1995; Williams et al, 1995) on CNBr-activated Sepharose.
The bound scFv was eluted with glycine-HCl (50 mM,
pH 2.5), EDTA (1 mM) and NaN3 (0.04%) and neutralized
immediately with sodium phosphate (4 M, pH 7). For the
•yR38 SCFV, a cell lysate was prepared by resuspending E.coli
cells in sucrose (20% v/v), Tris-HCl (pH 8.0), EDTA (1 mM)
and Triton X-100 (0.1%) for 5 min, followed by centrifugation
(27 000 g) to remove cellular debris. The 7R38 SCFV was
then purified as for the A6 scFv. scFv concentrations were
determined by quantitative amino acid analysis.
Gel filtration
Analytical gel filtration chromatography was performed on an
Ultropac TSK G3000SW column (7.5X600 mm) equilibrated
with MOPS (40 mM, pH 7.5) and Ca(OAc)2 (100 mM) at a
flow rate of 0.7 ml/min. The column was calibrated using
BSA (Mr 67 000), ovalbumin (Mr 43 000), carbonic anhydrase
(Mr 29 000) and ribonuclease A (Mr 13 700).
Biosensor measurements
The intact extracellular IFN7R produced in insect cells (Gentz
et al, 1992) was immobilized on CM5 sensor chips by the
random amine coupling method described in the BIAcore
methods manual (Pharmacia). Binding curves, measured in
duplicate, were recorded under the following conditions: A6
scFv—injection volume 40 (il, flow rate 10 jil/min, HBS buffer
pH 8, HEPES (10 mM), NaCl (150 mM), EDTA (3.4 mM),
surfactant P20 (0.005%), concentrations of scFv tested 38, 47,
66, 76, 85, 95, 104, 114 nM; ?R38 scFv—injection volume
30 |xl» flow rate 10 (il/min, HBS buffer pH 7.4, concentrations
of scFv tested 20, 40, 60, 80, 100, 140, 180, 220 nM; and
7R99 scFv—injection volume 30 ul, flow rate 20 |il/min,
phosphate buffer (50 mM, pH 7.2), NaCl (150 mM), with P20
(0.005%) concentrations of scFv tested 6, 8, 10, 12, 14, 16,
18,20 nM. After each measurement the surface was regenerated
with glycine buffer (10 \il, 0.1 M, pH 2.0). The specificity of
each interaction was tested using a control surface, and by
preincubation of each scFv with the intact IFN7R or with
thioredoxin (Trx)-IFNYR fragment fusion proteins (Ruegg
et al, 1995; Williams et al, 1995). Preincubation of A6 and
-yR38 scFvs with the intact IFNyR or the Trx-IFNTR1"108 fusion
protein inhibited binding of scFv to the biosensor, whereas
Trx-IFN7«100-229 had no effect. For the yR99 scFv, the
intact IFNjR and Trx-IFNiR100-229 inhibited binding and Trx-
i-ios had no inhibitory effect, as anticipated.
Anti-lnterferon y receptor antibody fragments
Radioimmunoassays
Raji cells (107 cells/ml) in Hanks BSS with 1% BSA and
HEPES buffer (15 mM, pH 7.2) were aliquoted (100 nl = 106
cells) into wells in a COSTAR 96U-well microtitre plate each
containing [1 2 5I]IFNY (-2.5 ng, 1.5X104 c.p.m./ng) and scFv
protein in the concentration range 0.1-10"6 mg/ml). After
incubation at 4°C for 90 min, the plates were centrifuged
(1500 r.p.m., 5 min) and the supernatant was discarded. The
cells were washed twice with Hanks BSS with 0.1% BSA in
HEPES buffer (15 mM, pH 7.2) and 0.01% Triton X100. The
amount of [l25I]IFNy bound to the cells was determined by
liquid scintillation counting (Garotta et al, 1990). The assays
were performed in triplicate and the results given are the mean
values (Table IT).
Peptide synthesis
Linear peptides were assembled on an ABI430A synthesizer
(Applied Biosystems, Foster City, CA), using Fmoc chemistry.
Each HPLC-purified peptide gave a satisfactory amino acid
analysis, a molecular ion (M + H or M + Na) on electrospray
mass spectrometry and 600 MHz 'H NMR spectra that were
consistent with the expected connectivity. Cyclic peptides were
assembled in the same way except that Fmoc-Cys(Trt)-COO-
p-alkoxybenzyl alcohol resin (Bachem, Switzerland) was used
to initiate the synthesis, the fully assembled peptides were
bromoacetylated, the. resin was then treated with TFA con-
taining water (5% v/v), thioanisole (5% v/v), phenol (5% v/v)
and triisopropylsilane (5% v/v), and cyclization was performed
in acetonitrile-water (1:1, ~1 mg/ml) at pH 8 (NH3), with
stirring under N2 for 14 h. The cyclic peptides were also
purified by reversed-phase-HPLC and characterized by elec-
trospray mass spectrometry and 600 MHz ID and 2D NMR
spectrometry.
Inhibition assays
Competitive ELISA was performed by minor variation of an
established method (Ozmen et ai, 1992). Competitive binding
assays were performed with the BIAcore apparatus. Intact
antibody and free (linear or cyclic) peptide were co-injected
over immobilized receptor. No inhibition of antibody binding
to the biosensor in the presence of up to ~500 (JM peptide
concentration could be detected.
Results
Cloning and expression of scFv genes
Genes encoding scFv fragments derived from the mAbs A6,
?R38 and TR99 were assembled by PCR (Marks et al, 1991)
from cDNAs encoding individual H- and L-chains (Bridges
et al., 1995). Each VH and VL was connected via a linker
encoding the peptide (GGGGS)3, in the order Vn-linker-VL.
The three scFv genes were each cloned as Sfil-Notl fragments
into the phagemid vector pHENl, in-frame behind a pelB
leader sequence, and before a linker encoding a peptide c-myc
tag, such that the tag is attached to the C-terminus of VL in
the scFv (Hoogenboom et al, 1991). The anti-myc tag mAb
9E10 (Evan et al, 1985) was used to detect secretion of
soluble scFv after growth in E.coli HB2151 and induction
with IPTG at 30°C. No significant improvement in yield was
observed by induction at lower temperatures. Production of
the A6 and the yR99 scFv gave rise to extensive cell lysis,
whereas cell division continued after induction of the -yR38
scFv, which could subsequently be isolated from a per-
iplasmic extract.
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Fig. 1. Elution profile of each scFv from a gel filtration chromatographic
column (see Results and Materials and methods sections). S = salt peak;
M=elution volume expected for monomeric scFv; D=elution volume
expected for dimeric scFv.
Purification and characterization of scFvs
An immunoaffinity column of 9E10 mAb coupled to Sepharose
was used to isolate scFv fused to the peptide tag from the
culture supernatant or a periplasmic extract. Functionally active
scFv protein was further purified by affinity chromatography
using recombinant IFN7R fragments immobilized on
Sepharose. The native-like N-terminal IFN7R domain (Willi-
ams et al, 1995) fused to thioredoxin (Trx-IFN-yR1-108) was
used for the A6 and yR38 scFvs, and the membrane proximal
IFN7R domain as a thioredoxin fusion protein (Ruegg et al,
1995) (Trx-rFN-yft100-229) for -yR99 scFv. This affinity purifica-
tion step afforded in each case >95% homogeneous scFv,
with the correct relative mass by SDS-PAGE, and the expected
N-terminal amino acid sequence. The yields were yR99 SCFV
(<0.2 mg/1), A6 scFv (-0.3 mg/1) and yR38 scFv (-1-2 mg/1).
Upon gel filtration chromatography, >95% of each protein
eluted close to the volume expected for monomeric scFv
(Figure 1). The A6 scFv eluted slightly slower than expected,
but this property was also shared by A6 Fab fragment. The
yR99 scFv and to a lesser extent the A6 scFv precipitated
irreversibly from even dilute solutions (<1 mg/ml) upon
storage at 4°C. The yR38 scFv was stable over several weeks
at 4°C and remained soluble in more concentrated solutions
(up to several mg/ml).
Isolated Vfj- and VL-chains
Each VH and VL gene from A6, YR38 and yR99 was amplified
separately by PCR and cloned as a Sfil-Notl fragment into the
phagemid vector pHENl (Hoogenboom et al, 1991), as
described above for the scFvs. Production of tag-positive
material after growth in E.coli HB2151 and induction with
IPTG was detected with the 9E10 mAb. Although in several
cases soluble tag-positive proteins were found, none was able
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Table I. Sequences of linear and cyclic peptides derived from individual CDRs of mAbs A6, "jfR38 and 7R99
Antibody A6
CDRL1 Ac-LysAlaSerGluAspIleTyrAsnArgLeuAla-OH
CDRL2 Ac-LeuIleSerGlyAlaThrSerLeuGluThrGluValProSer-OH
CDRL3 Ac-GlnGlnTyrTrpSerThrTrpThrPheGly-OH
CDRH1 Ac-SerGlyPheSerLeuThrThrTyrGlyMetGly ValGlyTrp-OH
CDRH2 Ac-AlaHisIleTrpTrpAspAspAspLysTyrTyr-OH
CDRH3 Ac-AlaArgArgAlaProPheTyrGlyAsnHisAlaMetAspTyr-OH
CYCLL1 Cyclo(S.Ac-AlaLysAlaSerGluAspIleTyrAsnArgLeuAlaCys-OH)
CYCLL2 Cyclo(S.Ac-LcuIleSerGlyAlaThrSerLeuGluCys-OH)
CYCLL3 Cyclo(S.Ac-AlaGlnGlnTyrTrpSerThrTrpThrPheCys-OH)
CYCLH1 Cyclo(S.Ac-SerPheSerGlyPheSerLeuThrThrTyrGlyMetGlyValGlyCys-OH)
CYCLH2 Cyclo(S.Ac-HisIleTrpTrpAspAspAspLysTyrCys-OH)
CYCLH3 Cyclo(S.Ac-ArgAlaProPheTyrGlyAsnHisAlaMetCys-OH)
Antibody yR38
CDRL3 Ac-GlnGlnTyrTrpSerThrProTyrThrPheGly-OH
CDRH1 Ac-SerGlyPheThrPheSerAsnTyrTrpMetAsn-OH
CDRH2 Ac-AlaGluIleArgLeuLysSerAsnAsnTyrAlaThrHisTyrAla-OH
CDRH3 Ac-ThrTcpTyrAspGlySerTyr-OH
CYCLL3 Cyclo(S.Ac-GlnGlnTyrTrpSerThrProTVrThrPheCys-OH)
CYCLH 1 Cyclo(S. Ac-Val AlaSerGlyPheThrPheSerAsnTyrTrpMetAsnCys-OH)
CYCLH2 Cyclo(S.Ac-ArgLeuLysSerAsnAsnTyrAIaCys-OH)
CYCLH3 Cyclo(S.Ac-ThrTrpTyrAspGlySerTyrTrpCys-OH)
Antibody yR99
CDRL1 Ac-ArgSerSerGlnSerLeuAlaAsnSerTyrGlyAsnThrTyrLeuSer-OH
CDRL2 Ac-LeuIleTyrGlylleSerAsnArgPheSer-OH
CDRL3 Ac-LeuGlnGlyThrHisGlnProTrpThrPheGly-OH
CDRH1 Ac-LysAlaSerGlyTyrThrPheThrThrTyrThrMetHisTrp-OH
CDRH2 Ac-IlcGlyTyrlleAsnProSerSerGlyTyrThrGluTyrAsnGln-OH
CDRH3 Ac-Cys(Acm)VaJArgSerArgArgValProAspTyrTrpGly-OH
CYCLL 1 Cyclo(S.Ac-ArgSerSerGlnSerLeuAlaAsnSerTyrGlyAsnThrTyrLeuSerCys-OH)
CYCLL2 Cyclo(S.Ac-LeuIleTyrGlyIleSerAsnArgCys-OH)
CYCLL3 Cyclo(S.Ac-GlnGlyThrHisGlnProTrpThiCys-OH)
CYCLH 1 Cyclo(S.Ac-GlyLysAlaSerGlyTyrThrPheThrThrTyrThrMetCys-OH)
CYCLH2 Cyclo(S.Ac-TyrIleAsnProSerSerGlyTyrThrGluCys-OH)
CYCLH3 Cyclo(S.Ac-ArgSerArgArgValProAspTyrCys-OH)
The linear peptides are labelled according to H-chain (HI-3) or L-chain (LI-3) CDR, and CYCL indicates the corresponding cyclic peptides. Note that the L-
chains of A6 and -yR38 have identical LI and L2 CDR sequences since both mAbs use the same Vk34C germline gene (Bndges et al., 1995).
to bind the IFN7R fragments immobilized on Sepharose. Triple
G44E, L45R and W47G mutations were introduced into each
VH-chain by site-directed mutagenesis. All three mutated VH-
chains could be produced in a soluble form in E.coli HB2151
following induction with IPTG. However, none of these
proteins retained significant IFNYR binding activity.
CDR peptides
Sequence comparisons of each Fv with the structural database
(Chothia et al, 1989; Bridges et al, 1995) were used to
determine which amino acid residues are likely to be located
in CDR loops. These, together with one or more residues
from the flanking framework regions, were incorporated into
synthetic linear peptides, as shown in Table I. Cyclic derivatives
were made separately by starting the synthesis with cysteine
at the C-terminus, addition of a bromoacetyl group at the
N-terminus and subsequent cyclization by displacement of
bromine with the S atom of cysteine, to afford a thioether.
The ability of each linear and cyclic peptide to compete
with intact mAb for binding recombinant IFN-yR was analysed
on a BIAcore instrument and by ELISA. In both assays, no
inhibitory activity (up to ~0.5 mM peptide) was found amongst
the peptides investigated.
368
Biosensor measurements and radioimmunoassay
The receptor affinity and inhibitory activity of each scFv
protein was analysed on a BIAcore instrument and by radio-
immunoassay using native receptor on human Raji cells. For
BIAcore measurements, the amount of recombinant insect cell-
derived (Gentz et al, 1992) WNyR immobilized on the
biosensor chip was selected to give responses that could be
fitted accurately to a monoexponential function (Karlsson et al.,
1991). The dissociation rate constants were determined by
non-linear fitting of the dissociation phase to an integrated
form of the first-order rate equation. Two methods of fitting
the association phases were then used. The first makes use of
the fcoff value to determine k^ by direct non-linear fitting of
the instrument response to an integrated form of the rate
equation, using protocols supplied by the manufacturer (Pharm-
acia). In the second method (Karlsson et al, 1991), the
response is used to calculate k^, where k^ = konC + koff, and
a linear regression of a secondary plot of ks against C yields
km and fc^. Within experimental error, both methods gave the
same values for the interaction constants. Binding curves from
duplicate assays at eight analyte concentrations were analysed
for each scFv (see Figure 2). Owing to the high k^ observed
for the 7R99 scFv [seen also for the intact mAb in earlier
Anti-interferon y receptor antibody fragments
A6 scFv
) 120 240 360 480 600
42 120- yR38 scFv
200 400 600
100 150
Time (s)
Fig. 2. Sensorgrams from a Pharmacia BIAcore instrument for scFv binding
to immobilized recombinant IFNyR. The amount of IFNyR immobilized on
the biosensor was varied by adjusting the exposure time of biosensor
surface to activation reagent and of protein to the activated surface.
Activation of the sensor surface was with NHS (50 mM) and EDC (0.2 M),
and coupling to IFN7R was performed in sodium citrate buffer (10 mM,
pH 3.95).
Itoble II. Kinetic and thermodynamic parameters for binding of scFvs
derived from mAbs A6, yR3& and 7R99 to the recombinant human IFN7R
by BIAcore measurements and IC50S for inhibition of IFNy binding to the
native receptor on human Raji cells
scFv (X10"3 *„ , (X105 M- ' s-1) KD (nM) IC50 (nM)
A6 10.4 ± 0.1
7R38 9.2 ± 0.3
7R99 6.9 ± 0.5
5.3 ± 0.2
3.3 ± 0.4
63.8 ± 0.5
20.0
27.8
1.1
10.3
25.8
8.5
work (Williams et al., 1995)], the level of immobilized receptor
had to be reduced to a low level to avoid mass transport
limitation. Binding reactions run at different flow rates, and
use of the BIAsimulation software indicated that none of the
data used for estimation of K&S was influenced significantly
by mass transport limitation. The interaction constants deter-
mined in this work are given in Table n.
The ability of each scFv to inhibit the binding of I25I-
labelled IFNy to human Raji cells (Aguet and Merlin, 1987),
which overexpress the IFNyR, was also tested by radioimmuno-
assay (Figure 3). The concentration of scFv needed to reduce
the amount of bound [ I 2 5I]IFNY by 50% (IC50) is also given
in Table n.
A6 scFv
yR38 scFv
SCFV
c
E
*
3
O
o
concentration nM
Fig. 3. Concentration-dependent inhibition of ['^IJIFNy binding to human
Raji cells by the A6, "|fR38 and yR99 scFvs using radioimmunoassay (see
Materials and methods).
Discussion
The Fv region, comprising the entire variable region of the H-
and L-chains, is the smallest fragment of an antibody that
contains an intact copy of the antigen binding site. As such,
it can be expected to maintain consistently the antigen-binding
specificity and affinity of the whole antibody (Raag and
Whitlow, 1995). Further dissection of the Fv fragment may
lead to isolated VH- or VL-chains, which in some cases have
been observed to retain a high antigen-binding affinity (Ward
et al, 1989; Monfardini et al, 1995). However, the production
of individual VH-chains can be problematic owing to low
expression and poor solubility. Attempts have been made to
engineer the exposed interface on VH for the light chain
(Davies and Riechmann, 1994) to increase hydrophilicity, as
seen in camelid antibodies which occur naturally as heavy
chains without a light chain partner (Hamers-Casterman
et al, 1993).
In this work, three scFv fragments, derived from mAbs A6,
yR38 and yR99, have been produced in E.coli, and isolated as
soluble monomeric proteins that retain a high affinity for the
recombinant human IFNyR (Table II). The relative affinities
of the intact mAbs for the IFNyR, measured in earlier work
using a laboratory-built SPR biosensor (Williams et al, 1995),
are similar within a factor of 2-3 to those measured in this
work for the scFvs on a Pharmacia BIAcore instrument. The
A6 and yR38 scFvs, which bind the N-terminal Ig-like domain
of the IFNyR, have dissociation constants (KQS) of 20 and
28 nM, respectively. The yR99 scFv binds an epitope in the
membrane proximal domain of the receptor, which includes
residues in the interdomain linker region (Ruegg et al, 1995),
with a KD of ~1 nM. Moreover, as found in earlier work with
intact mAbs, the higher relative affinity for the immobilized
receptor shown by the yR99 SCFV, under these conditions,
arises largely from an increased A^ ,, rather than a lower off-rate.
The soluble scFvs also retain the ability of the whole mAbs
to inhibit the binding of IFNy to the native receptor on human
Raji cells (Table II). The inhibitory activities expressed as IC50
values lie between 9 and 26 nM, which is approximately an
order of magnitude weaker than the IC50S seen for the intact
mAbs (Bridges et al, 1995). This is most likely due to an
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avidity effect with the whole antibody, since the Fab fragments
derived from each mAb have IC50S that, within a factor of 2,
are similar to those observed for the scFvs (data not shown).
These results also show that the inhibitory effect of each mAb
is caused by the association of the variable domain with the
receptor, rather than steric exclusion of the hormone binding
site by the antibody constant regions. The X-ray crystal
structure of the IFNy-IFN'yR complex has revealed that the
hormone binding site is centrally located in the rod-shaped
IFN7R molecule and comprises residues from both Ig-like
domains (Walter et ai, 1995). Most likely the structural
epitopes bound by each mAb overlap, at least partially,
the hormone binding site on the receptor, although other
mechanisms of inhibition, such as allosteric changes in receptor
conformation upon antibody binding, cannot be ruled out
at present.
Attempts to produce individual, native-like VH- and VL-
chains from each mAb failed to afford soluble protein that
bound to the IFN7R. Of the VH proteins, only those from
antibodies A6 and yR38 could be isolated directly in a soluble
form, following immunoaffinity chromatography using an anti-
C-terminal peptide tag mAb. The *yR99 VH gave no soluble
tag-positive protein in the expression system used here. To
overcome potential problems arising from low solubility and
non-specific interactions through the VL interface, triple G44E,
L45R and W47G mutations were introduced into each VH-
chain by site-directed mutagenesis, in analogy with camelid
antibodies (Davies and Riechmann, 1994). All three
'camelized' VH-chains could be produced in a soluble form in
E.coli HB2151 following induction with IPTG. However, none
of these proteins retained significant IFN7R binding activity.
No IFN7R binding activity was observed with VL-chains
produced in this way, or with linear and cyclic peptides derived
from the individual CDR sequences of each mAb (Table I).
The inability of the linear and cyclic peptides derived from
individual CDR sequences (see Table I) to bind the IFN7R is
most Likely due to the absence in each of a sufficient number
of the key residues that contribute significantly to the energetics
of receptor binding, and/or to the fact that these are not
displayed in the correct conformation. This point may be
addressed quantitatively in future work by detailed structural
and thermodynamic studies on native and mutant Fv-receptor
complexes. This should now be feasible with the ability to
produce both the mAb Fv fragments and native-like IFN7R
fragments in E.coli, combined with the application of NMR
and crystallographic techniques for structure determination.
The de novo design of new small-molecule ligands for the
IFN7R, that block the cytokine binding site and act as antagon-
ists, remains a considerable challenge. Conceivably, such
molecules may be derived by design of small-molecule peptide
mimetics of the key CDR loops derived from the mAbs
described here. However, detailed mutagenesis studies on two
different Fv fragment-protein antigen complexes (Hawkins
et al., 1993; Kelley and O'Connell, 1993) have shown already
that the antibody residues which appear to be most important
for antigen binding are grouped near the centre of the interface,
and are located in more than one CDR loop. If these findings
prove to be common, it seems likely that a general approach
to mimetic design must take into account the necessity of
retaining groups located in several CDRs to achieve high
antigen-binding affinity. Possible solutions to this design prob-
lem may be found by grafting multiple loops on to alternate
protein frameworks, for example a designer minibody (Martin
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et al, 1994), or possibly by their incorporation into template-
assembled synthetic proteins (Mutter and Vuilleumier, 1989).
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